Dear shareholders and prospective shareholders,
We remain optimistic about CRH Medical’s future. We have a safe and highly efficacious product (the CRH O’Regan System) for the treatment of hemorrhoids, coupled with a compelling market opportunity.
The market opportunity was reinforced this month by an article published on ABC News’ website. The article showed that the top trending search healthcare issue in the U.S. in 2012 was “hemorrhoids,” according to Google’s yearly summary of the world’s search trends.
A link to the article can be found here:
As the need for an effective treatment gains prominence, CRH Medical is increasingly being recognized as a market leader for the training and treatment of hemorrhoids.
The market need is one of the key drivers behind our decision to launch our Clinical Sales Support Program earlier this year.
Update on the Clinical Sales Support Program
CRH’s Clinical Sales Support Program ramped up in December. Our dedicated representatives in Miami, Atlanta, San Antonio/Houston and Dallas made important progress with the gastroenterologists in their respective territories, visiting 123 practices already trained on the CRH O’Regan System, and introducing the product to 101 new practices.
To date, we’re encouraged by the interactions our representatives are having with current and prospective customers.
Attending the New York Society for Gastrointestinal Endoscopy Annual New York Course
On December 19, we attended the New York Society for Gastrointestinal Endoscopy 36th Annual New York Course. The event, sponsored by Albert Einstein College of Medicine and New York Society for Gastrointestinal Endoscopy, was an excellent forum to introduce the Company and the O’Regan System to national and international practicing gastroenterologists, surgical endoscopists, GI fellows, and GI nurses and associates.
For CRH Medical, it was also an opportunity to reinforce relationships with key opinion leaders in the GI community, and reconnect with physicians utilizing the CRH O’Regan System.
Earlier in December, we set out on a two-day, non-deal roadshow in Toronto where we met with more than a dozen brokers, and a number of institutions.
The market feedback on the CRH story continues to be largely positive. Several prospective investors have communicated that they believe our market opportunity is so significant that the Company is at an inflection point now. Others want to see the impact that the Clinical Sales Support Program will have on our revenues before making an investment decision on CRH.
Plans for January
We intend to stay visible with our GI customers this month by attending two prominent gastrointestinal conferences: the AGA-ASGE Clinical Conference in San Diego, and the American College of Gastroenterology Western Regional Postgraduate Course in Los Angeles. Having a presence at both conferences ultimately supports our revenue growth, which is going to be our main focus in 2013.
We look forward to sharing the January edition of the CRH Investor Bulletin with you, and as always, we appreciate your interest and support.
Adam Peeler, Media and Investor Relations
416.815.0700 x 225